Tenderwize
Zurück zur Suche

Open-house rebate agreements for infliximab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Jan 31, 2028 · 523 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Infliximab, ATC L04AB02

18/100

Opportunity Score

Needs reviewHigh complexity
SuppliesOpen
Warum diese Bewertung?

Chance

18 / 100

Komplexität

68 / 100

Risikofaktoren

The structured notice suggests a long-running open-house arrangement, but the extracted XML notice says the procedure w...

The structured data marks electronic submission as not allowed, while the notice text allows electronic submission with...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Mar 2028
  • Non-exclusive open-house rebate agreements for medicinal products with the active substance infliximab (ATC L04AB02).
  • Exclusion of medicines listed on the BfArM list under § 35 Abs. 5a SGB V (children's medicines).
Vollständige Zusammenfassung anzeigen

This is an open-house pharmaceutical supply arrangement for infliximab (CPV 33600000) by AOK Rheinland-Pfalz/Saarland. The structured notice indicates a 24-month term starting 2026-04-01, but the extracted TED XML notice states the open-house procedure was lifted effective 2026-05-31 and no new contracts can be concluded. This creates a material inconsistency that materially affects bid viability. The procedure is non-exclusive, with no selection decision and no negotiated terms, but participation is limited to pharmaceutical companies and requires specific submission formats and proof of marketability/authorization.

Risiken

The structured notice suggests a long-running open-house arrangement, but the extracted XML notice says the procedure w...

The structured data marks electronic submission as not allowed, while the notice text allows electronic submission with...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Only approved and marketable medicines in Germany may be supplied under the contract.

Eligibility

  • Only pharmaceutical companies are eligible to participate.

Administrative

  • If the product is not yet listed in Lauer-Taxe at submission time, an AMIce public-section extract must be provided.

Auftraggeber

Lose (1)

LOT-0001

Open-house rebate agreements for infliximab

Single lot covering non-exclusive open-house rebate agreements for medicinal products containing infliximab (ATC L04AB02). The scope excludes medicines on the BfArM list under § 35 Abs. 5a SGB V (children's medicines). Contract terms are uniform for all participants; no individual negotiations are conducted. The extracted XML notice says the procedure was withdrawn effective 2026-05-31, so new contract entry is no longer possible according to that source.

SuppliesEU fundedElectronic submission

Ort

Eisenberg, Germany

Dauer

Mar 2026 - Mar 2028

Kategorie

Pharmaceutical products

Frist

Deadline Jan 31, 2028

Vergabedetails

Veröffentlichungsdatum
08 Apr 2026
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
241570-2026

Dokumente (1)

Ähnliche Ausschreibungen